microarray analysis
Dotaz
Zobrazit nápovědu
Metallothioneins (MTs), low molecular mass cysteine-rich proteins, which are able to bind up to 20 monovalent and up to 7 divalent heavy metal ions are widely studied due to their functions in detoxification of metals, scavenging free radicals and cells protection against the oxidative stress. It was found that the loss of the protective effects of MT leads to an escalation of pathogenic processes and carcinogenesis. The most extensive area is MTs expression for oncological applications, where the information about gene patterns is helpful for the identification biological function, resistance to drugs and creating the correct chemotherapy. In other medical applications the effect of oxidative stress to cell lines exposed to heavy metals and hydrogen peroxide is studied as well as influence of drugs and cytokines on MTs expression and MTs expression in the adipose tissue. The precise detection of low metallothionein concentrations and its isoforms is necessary to understand the connection between quantity and isoforms of MTs to size, localization and type of cancer. This information is necessary for well-timed therapy and increase the chance to survival. Microarray chips appear as good possibility for finding all information about expression of MTs genes and isoforms not only in cancer, but also in other diseases, especially diabetes, obesity, cardiovascular diseases, ageing, osteoporosis, psychiatric disorders and as the effects of toxic drugs and pollutants, which is discussed in this review.
This study combines mRNA and protein analysis using cDNA and antibody microarray techniques, respectively. These create a novel, integrated perspective into cellular molecular profiles. The aims of this study were to establish a reliable way of integrating these two approaches in order to obtain complex molecular profiles of the cell and to find suitable methods to normalize the data obtained using these approaches.
Antibody microarray and cDNA microarray techniques were used to study expression alterations in HL-60 cells that were differentiated into granulocytes using all-trans retinoic acid (ATRA). We selected this model to evaluate this combined profiling technique because the expression levels of most of the mRNA and protein species in these cells are not altered; therefore it is easier to track and define those species that are changed. The proteins whose levels were altered included c-myc, c-jun, Pyk2, FAK, PKC, TRF1, NF-kappaB and certain caspase types. These proteins are involved in apoptosis and hematopoietic differentiation pathways, and some have also been reported to have oncogenic potential. We compared the results obtained using the two methods, verified them by immunoblotting analysis, and devised normalization approaches.
This is one of the first demonstrations that a combination of antibody microarray and cDNA microarray techniques is required for complex molecular profiling of cells based on multiple parameters. This approach allows a more detailed molecular phenotype of the given sample to be obtained. The results obtained using a combination of the two profiling methods are consistent with those from previous studies that used more traditional methods.
Keywords: microarray, cell profiling, protein expression, mRNA expression, HL-60.- MeSH
- čipová analýza proteinů MeSH
- financování organizované MeSH
- fokální adhezní kinasa 2 analýza MeSH
- geny myc MeSH
- HL-60 buňky MeSH
- lidé MeSH
- messenger RNA analýza MeSH
- protein TRF1 analýza MeSH
- sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů MeSH
- tretinoin farmakologie MeSH
- Check Tag
- lidé MeSH
The combination of microarray technologies with microfluidic sample delivery and real-time detection methods has the capability to simultaneously monitor 10-1000 s of biomolecular interactions in a single experiment. Despite the benefits that microfluidic systems provide, they typically operate in the laminar flow regime under mass transfer limitations, where large analyte depletion layers act as a resistance to analyte capture. By locally stirring the fluid and delivering fresh analyte to the capture spot, the use of passive mixing structures in a microarray environment can reduce the negative effects of these depletion layers and enhance the sensor performance. Despite their large potential, little attention has been given to the integration of these mixing structures in microarray sensing environments. In this study, we use passive mixing structures to enhance the mass transfer of analyte to a capture spot within a microfluidic flow cell. Using numerical methods, different structure shapes and heights were evaluated as means to increase local fluid velocities, and in turn, rates of mass transfer to a capture spot. These results were verified experimentally via the real-time detection of 20-mer ssDNA for an array of microspots. Both numerical and experimental results showed that a passive mixing structure situated directly over the capture spot can significantly enhance the binding rate of analyte to the sensing surface. Moreover, we show that these structures can be used to enhance mass transfer in experiments regarding an array of capture spots. The results of this study can be applied to any experimental system using microfluidic sample delivery methods for microarray detection techniques.
The left and right ventricle originate from distinct parts of the cardiac tube, and several genes are known to be differentially expressed in these compartments. The aims of this study were to determine developmental differences in gene expression between the left and right ventricle, and to assess the effect of altered hemodynamic loading. RNA was extracted from isolated left and right normal chick embryonic ventricles at embryonic day 6, 8, and 10, and from day 8 left atrial ligated hearts with hypoplastic left and dilated right ventricles. cRNA was hybridized to Affymetrix Chicken Genome array according to manufacturer protocols. Microarray analysis identified 302 transcripts that were differentially expressed between the left and right ventricle. Comparative analysis detected 91 genes that were different in left ventricles of ligated hearts compared to age-matched ventricles, while 66 were different in the right ones. A large number of the changes could be interpreted as a delay of normal maturation. The approach described in this study could be used as one of the measures to gauge success of surgical procedures for congenital heart disease and help in determining the optimal time frame for intervention to prevent onset of irreversible changes.
- MeSH
- hemodynamika MeSH
- kuřecí embryo MeSH
- mikročipová analýza MeSH
- myokard metabolismus MeSH
- srdeční komory embryologie metabolismus MeSH
- srdeční síně embryologie metabolismus MeSH
- transkriptom MeSH
- zvířata MeSH
- Check Tag
- kuřecí embryo MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
DiGeorgeův syndrom (velokardiofaciální syndrom, VCFS, 22q11DS) je způsobený mikrodelecemi přibližně 40 genů na jedné kopii chromosomu 22. Projevem syndromu je variabilní kombinace více než 190 fenotypových příznaků, mezi nejčastější patří vrozené vady srdce, orofaciální rozštěp a velofaryngeální insuficience. Končetinové defekty v oblasti rukou a nohou nepatří do klasického klinického obrazu DiGeorgeova syndromu. Cílem práce bylo u pacienta s typickým fenotypovým projevem 22q11DS a současně s raritním nálezem těžké ektrodaktylie na všech čtyřech končetinách zhodnotit rozsah genomické odchylky metodou celogenomových SNP arrayí za účelem vysvětlení končetinové vady. Bylo provedeno vyšetření metodou FISH, sekvenace genu TP63 a celogenomová SNP array pomocí kitu HumanCytoSNP-12 DNA Analysis Beadchip (Illumina Inc.). Metodou FISH byl potvrzen DiGeorgeův syndrom, sekvenace genu TP63 neodhalila patogenní mutaci, vyšetření metodou SNP arrayí potvrdilo deleci v oblasti 22q11.2 obvyklého rozsahu 2,9 Mb. Nebyla potvrzena původní hypotéza, že by se u pacienta mohlo jednat o deleci 22q11.2 většího rozsahu, než je obvyklé, která by zahrnovala gen asociovaný s vývojem končetin a vysvětlila těžký končetinový defekt. Ačkoli končetinové defekty nepředstavují typickou patologii v rámci DiGeorgeova syndromu, je nutno myslet na tuto diagnózu u každého novorozence s vrozenou srdeční vadou, rozštěpem obličeje a anomáliemi končetin. Přestože je u DiGeorgeova syndromu běžná značná variabilní expresivita, nelze u našeho pacienta vyloučit také náhodnou koincidenci dvou nezávislých genetických vad, DiGeorgeova syndromu v důsledku mikrodelece 22q11.2 a ektrodaktylie způsobené mutací jiného/jiných genů.
DiGeorge syndrome (velocardiofacial syndrome, VCFS, 22q11DS) is caused by a microdeletion of approximately 40 genes from one copy of chromosome 22. Expression of the syndrome is a variable combination of more than 190 phenotypic characteristics, the most common are congenital heart disease, cleft palate and velopharyngeal insufficiency. Limb anomalies of hands and feets are not a typical clinical symptoms of DiGeorge syndrome. The aim of the study was to evaluate the extent of genomic changes in a 4.5 years old child with classical phenotypic features of 22q11DS in combination with severe ectrodactyly of all four limbs in addition; using microarray based single nucleotide polymorphism techniques in order to explain the origin of limb anomaly defects. FISH analysis, TP63 gene sequencing and whole genome SNP array analysis using HumanCytoSNP-12 DNA Analysis Beadchip (Illumina Inc.) were performed. FISH method revealed DiGeorge syndrome, TP63 gene sequencing did not detect any deleterious mutation, microarray SNP analysis established microdeletion of 22q11.2 region in standard defined range of 2,9 Mb. The original possible hypothesis, that in a patient it could exist a much more genomic changes than only these related to 22q11.2 region, involving genes associated with limb development and formation and thus explaining devastating limbs damage in patient, unfortunately was not confirmed. Although limb defects do not belong to the typical pathogenic signs of DiGeorge syndrome, this diagnosis should be considered in all neonate with congenital heart defect, cleft palate and limb anomalies. Even though variable phenotypical expressivity in DiGeorge syndrome is frequent, we can not exclude the possibility of coincidence of two independent genetic defects in our patient; DiGeorge syndrome due to 22q11.2 microdeletion and ectrodactyly which results of another gene/s mutation.
- Klíčová slova
- SNP microarray, ektrodaktylie, ruka s rozštěpem, klepeto, split hand/split foot malformation,
- MeSH
- chromozomální delece MeSH
- cytogenetické vyšetření MeSH
- DiGeorgeův syndrom * diagnóza genetika MeSH
- fenotyp MeSH
- hybridizace in situ fluorescenční MeSH
- lidé MeSH
- lidské chromozomy, pár 22 MeSH
- nádorové supresorové proteiny genetika MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- rozštěp patra MeSH
- rozštěp rtu MeSH
- sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů MeSH
- syndaktylie MeSH
- transkripční faktory genetika MeSH
- vrozené deformity nohy (od hlezna dolů) MeSH
- vrozené deformity ruky MeSH
- vrozené srdeční vady MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- Publikační typ
- kazuistiky MeSH
- práce podpořená grantem MeSH
Ciele: Analýza prenatálnych vzoriek za obdobie 2015–2020. Porovnanie miery detekcie klinicky relevantných variant cytogenetickou analýzou karyotypu a cytogenomickými metódami MLPA (Multiplex Ligation-Depent Probe Amplification) a mikročipmi (CMA – chromosomal microarray). Súbor a metodika: Analyzovaných bolo 1 029 prenatálnych vzoriek cytogenetickým hodnotením karyotypu (n = 1 029), cytogenomickými metódami MLPA (n = 144) a CMA (n = 111). Všetky nebalansované zmeny boli potvrdené metódou MLPA alebo CMA. Výsledky: Z analyzovaného súboru plodov, po odčítaní aneuploidií – 107 (10,40 %, n = 1 029), bolo analýzou karyotypu zachytených 22 štruktúrnych aberácií (2,39 %, n = 922) – deväť nebalansovaných zmien (0,98 %), 10 balansovaných zmien (1,08 %), jeden prípad nejasnej mozaiky (0,09 %), jeden prípad prítomnosti marker chromozómu (0,09 %) a jeden prípad diskordancie pohlavia (0,09 %). U 255 vzoriek s fyziologickým karyotypom indikovaných k cytogenomickému vyšetreniu bolo zachytených celkom osem (7,21 %, n = 111) patologických variant metódou CMA. Metódou MLPA bolo z týchto ôsmich patogénnych variant zachytených päť (3,47 %, n = 144). Celkový záchyt patogénnych variant metódami MLPA a CMA vrátane konfirmačných vyšetrení patologického karyotypu je 14 (5,14 %) a 17 (6,25 %) (n = 272). Záchyt patologických variant v skupine s izolovanými poruchami bol nižší než v skupine s mnohopočetnými poruchami (5,08 vs. 21,42 %). Záver: Potvrdila sa vyššia úspešnosť záchytu patologických variant so zmenou v počte kópií, metódou CMA než MLPA.
Objective: Analysis of prenatal samples from 2015 to 2020. Comparison detection rates of clinically relevant variants by cytogenetic karyotype analysis and cytogenomic MLPA (Multiplex Ligation-Depent Probe Amplification) and microarray methods (CMA – chromosomal microarray). Material and method: 1,029 prenatal samples were analyzed by cytogenetic karyotyping (N = 1,029), cytogenomic methods – MLPA (N = 144) and CMA (N = 111). All unbalanced changes were confirmed by MLPA or CMA. Results: From the analyzed set of fetuses, after subtraction of aneuploidies – 107 (10.40%, N = 1,029), 22 structural aberrations (2.39%, N = 922) – nine unbalanced changes (0.98%), 10 balanced changes (1.08%), one case of unclear mosaicism (0.09%), one case of presence of a marker chromosome (0.09%) and one case of sex discordance (0.09%) – were detected by karyotype analysis. A total of eight (7.21%, N = 111) pathological variants were detected by CMA in 255 samples with physiological karyotype indicated for cytogenomic examination. Five (3.47%, N = 144) of eight pathogenic variants were detected by MLPA method. The total capture of pathogenic variants by MLPA and CMA methods was 14 (5.14%) and 17 (6.25%) (N = 272), including confirmatory pathological karyotype testing. Detection of pathological variants in the isolated disorders group was lower than in the multiple disorders group (5.08 vs. 21.42%). Conclusion: A higher success rate for the detection of pathological copy number variation variants by the microarray method than by the MLPA method was confirmed.
- MeSH
- klinická studie jako téma MeSH
- lidé MeSH
- mikročipová analýza metody MeSH
- mozaicismus MeSH
- multiplexová polymerázová řetězová reakce metody MeSH
- plod MeSH
- prenatální diagnóza * MeSH
- těhotenství MeSH
- variabilita počtu kopií segmentů DNA MeSH
- vrozené vady * diagnóza genetika MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
Background: Microarray technologies are used to measure the simultaneous expression of a certain set of thousands of genes based on ribonucleic acid (RNA) obtained from a biological sample. We are interested in several statistical analyses such as 1) finding differentially expressed genes between or among several experimental groups, 2) finding a small number of genes allowing for the correct classification of a sample in a certain group, and 3) finding relations among genes. Objectives: Gene expression data are high dimensional, and this fact complicates their analysis because we are able to perform only a few samples (e.g. the peripheral blood from a limited number of patients) for a certain set of thousands of genes. The main purpose of this paper is to present the shrinkage estimator and show its application in different statistical analyses. Methods: The shrinkage approach relates to the shift of a certain value of a classic estimator towards a certain value of a specified target estimator. More precisely, the shrinkage estimator is the weighted average of the classic estimator and the target estimator. Results: The benefit of the shrinkage estimator is that it improves the mean squared error (MSE) as compared to a classic estimator. The MSE combines the measure of an estimator’s bias away from its true unknown value and the measure of the estimator’s variability. The shrinkage estimator is a biased estimator but has a lower variability. Conclusions: The shrinkage estimator can be considered as a promising estimator for analyzing high dimensional gene expression data.
- MeSH
- exprese genu * genetika MeSH
- lidé MeSH
- mikročipová analýza * metody statistika a číselné údaje MeSH
- RNA * genetika MeSH
- statistické modely MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
Background: Hyperbaric oxygen (HBO2) therapy can have a positive effect on wound healing, angiogenesis and blood flow. No prior study has described the effects of HBO2 therapy and gene expression of this process. The goal of our research was to show the effects of HBO2 and its impact at the molecular level on angiogenesis, proliferation, differentiation, oxidative stress, inflammation, and extracellular matrix formation. Live animal subjects were used for simulating the process of wound healing under standard conditions and under the influence of HBO2. Methods: Two experimental groups were created using injured rabbits (N=24), one group (N=12) treated with hyperbaric therapy twice a day and one (N=12) with standard wound care management. Wounds were surgical, uninfected, and in healthy animal test subjects. We compared the whole genomic analysis of the transcriptome with the use of microarray technology at three intervals during treatment. Results: The induction of the wounds in rabbit skin increased expression of hundreds of genes in both treatment groups. The numbers of elevated and decreased genes gradually reduced as the wound healed. Gene expression analysis showed elevated expression of several genes associated with inflammation in both groups of injured animals. Genes connected to the process of angiogenesis, proliferation, differentiation, oxidative stress and extracellular matrix formation were without statistically significant changes. Conclusion: The evidence did not support that HBO2 had any significant effect on gene expression during wound healing. Additionally, there was no evidence to support that there were changes in gene expression in either treatment group.
- MeSH
- chirurgická rána genetika terapie MeSH
- čipová analýza tkání metody MeSH
- exprese genu * MeSH
- hojení ran genetika MeSH
- hyperbarická oxygenace * MeSH
- králíci MeSH
- kůže zranění MeSH
- messenger RNA analýza MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Wilsonova choroba (WCH) je závažné, autozomálně recesivní onemocnění, jehož podstatou jsou mutace v ATP7B genu, který kóduje měď-specifickou ATPázu. U postižených jedinců dochází k poruše vylučování toxické mědi z organismu a k jejímu hromadění v tělesných orgánech. Molekulární diagnostika Wilsonovy choroby je důležitou součástí stanovení správné diagnózy. Cílem práce bylo navrhnout a zvalidovat genotypovací DNA čip, který umožňuje současně analyzovat 87 mutací a 17 polymorfismů v ATP7B genu. Metody a výsledky. V první fázi validace bylo testováno 97 WCH pacientů se známým genotypem a 46 vzorků uměle připravených mutagenezí. Všechny analyzované sekvenční varianty byly detekovány se 100% správností. Ve druhé fázi validace byly testovány reálné vzorky WCH suspektních pacientů. Dosud jsme zanalyzovali 58 nepříbuzných pacientů, z nichž u 10 byla čipovou analýzou potvrzena diagnóza WCH, u 13 byla nalezena jedna mutace a u 35 žádná. U pacientů s jednou nebo žádnou detekovanou mutací následovalo přímé sekvenování kódující oblasti genu ATP7B, přičemž nebyla nalezena žádná další kauzální mutace. Závěry. Wilsonův čip se jeví jako rychlá a spolehlivá vyhledávací metoda mutací v ATP7B genu.
Wilson disease (WD) is a serious autosomal recessive disorder caused by mutations in ATP7B-gene which encodes a copper-specific ATPase. WD patients suffer from impaired biliary excretion of copper from organism and its' accumulation in body organs. Molecular diagnostics of WD is an important part of correct diagnosis statement. The aim of the study was to design and validate a genotyping DNA microarray which enables to analyze 87 mutations and 17 polymorphisms in ATP7B gene, simultaneously. Methods and Results. 97 WD patients with known genotypes and 46 samples prepared by mutagenesis were tested in the first phase of chip validation. All analyzed sequence variants were detected with 100% accuracy. Samples from WD suspected patients were tested in the second phase of validation. We have analyzed 58 unrelated patients, yet. The diagnosis of WD was confirmed in 10 patients, 13 patients were heterozygous for some mutation and 35 had no mutation in ATP7B gene. Samples with one or no mutation found by microarray analysis were sequenced directly and no further causal mutation was revealed. Conclusions. Wilson chip seems to be a fast and reliable method for screening of mutations in ATP7B gene.
